LUPIN
07.02.2022 - Jefferies on LUPIN Maintain Underweight CMP 804 Target 737
07.02.2022 - Kotak Inst Eqt on LUPIN Maintain Downgrade to Add from Buy CMP 804 Target 980(PREVTGT 1120)
15.12.2021 - CLSA on Lupin - Maintain Outperform - Cmp 946 Target 950
JPMORGAN ON LUPIN : 15.06.2021
* MAINTAIN UNDERWEIGHT TARGET: 965
* US FDA's warning letter to Lupin's Somerset unit brings risk to the forefront, JPMorgan cautious on the stock due to risk of earnings disappointment
* Warning Letter To Its Somerset Facility Brings The Risk To The Forefront
* There Is Visibility On The Pipeline That Is Factored Into Consensus Numbers
• Flawless Execution Has Become Imperative But Tough In The US Generic Mkt
* Risk Of Earnings Disappointment Keeps Us Cautious On The Stock
CLSA ON LUPIN : 14.06.2021
* MAINTAIN SELL TARGET: 1,080
* CLSA shares its view on Lupin after the co was issued a warnings letter by US FDA post its September-November 2020 inspection
• US FDA Issues Warning Letter After Inspection In Sep-Nov 2020
• The Facility Makes Up 5% Of Its Overall Sales
* Co Is Confident It Can Limit The Impact On Revenue & Resolve The Observations
* Do Not Build In Approvals For This Plant In FY22
• Delay In The Resolution Of This Plant Poses Downside Risk To FY23 Earnings Ests
